Overview

A Study Assessing GW870086's Potential to Cause Skin Thinning

Status:
Completed
Trial end date:
2011-07-07
Target enrollment:
Participant gender:
Summary
This study is a randomised, double-blind, placebo-controlled study of topical GW870086 to explore the potential for skin thinning in healthy adult volunteers after 42±2 days of treatment. Twenty (20) healthy volunteers will be randomised to receive placebo and GW870086 2% cream, they will also receive either of the following treatments: GW870086 0.2% cream, or clobetasol propionate 0.05% cream.
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Clobetasol